<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/PT-26-12-2025-shutterstock_2340757177-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/PT-26-12-2025-shutterstock_2340757177-430x241.jpg"/></p>
<p>RP-3467 是一种强效的小分子 Polθ 抑制剂，属于与 BRCA 突变和其他基因组改变相关的合成致死靶点。来源：PeopleImages/Shutterstock.com。</p>
<p>吉利德科学已签署协议收购 Repare Therapeutics 的聚合酶 theta (Polθ) ATP 酶抑制剂 RP-3467。</p>
<p>该交易涉及对 Repare 的总对价高达 3000 万美元，并直接影响公司的现金状况和即将进行的股东安排。</p>
<h3>深入了解 GlobalData</h3>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>报告</p>
<h4>NPVM: Repare Therapeutics Inc 的 RP-6306</h4>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>报告</p>
<h4>NPVM: Replimune Ltd 的 Vusolimogene Oderparepvec</h4>
<h5>深入了解 GlobalData</h5>
<p>商业智能的黄金标准。</p>
<p>了解更多</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>发现有效的 B2B 营销</h4>
<p>结合商业智能和编辑卓越，覆盖 36 个领先媒体平台的专业人士。</p>
<p>了解更多</p>
<p>根据条款，吉利德将向 Repare 支付 2500 万美元的预付款，受制于常规的扣留和调整，并在完成某些技术转让活动后再支付最多 500 万美元。</p>
<p>在 2025 年 11 月 14 日，Repare 宣布与 XenoTherapeutics 和 Xeno Acquisition 签署了最终安排协议。根据该协议，Xeno 同意购买 Repare 所有已发行和流通的普通股。</p>
<p>每位股东每股将收到的现金金额将基于 Repare 的结算现金余额，扣除与交易相关的费用和未偿债务后计算。</p>
<p>Polθ ATP 酶抑制剂收购的预付款增加了 Repare 的现金储备，从而提高了对股东支付的估计。</p>
<p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData 战略情报</p>
<h1>美国关税正在变化 - 你会反应还是预见？</h1>
<p>不要让政策变化让你措手不及。通过实时数据和专家分析保持主动。</p>
<p>来自 GlobalData</p>
<p>了解更多关于战略情报</p>
<p>根据修订后的现金余额，Repare 估计股东在交易完成时将获得约 2.20 美元的普通股每股收益。</p>
<p>Repare Therapeutics 总裁、首席执行官兼首席财务官 Steve Forte 表示：“我们很高兴宣布这一交易，它将吉利德在肿瘤研究和开发方面的领先专业知识与 RP-3467 这一潜在的最佳 Polθ ATP 酶抑制剂结合在一起。这是 Repare 今年第三笔也是最重要的投资组合交易。”</p>
<p>RP-3467 是一种强效的小分子 Polθ 抑制剂，属于与乳腺癌基因 (BRCA) 突变和其他基因组改变相关的合成致死靶点。</p>
<p>在 2025 年 5 月，Repare 与加拿大生物技术公司 DCx Biotherapeutics 签署了发现平台和知识产权 (IP) 的外部许可协议。</p>
<h2>制药技术卓越奖 - 提名已关闭</h2>
<p>制药技术卓越奖 的提名现已关闭。感谢所有参与的组织 - 你们的响应非常出色，展示了卓越的创新、领导力和影响力。</p>
<p><strong>行动中的卓越</strong></p>
<p>因在 综合制造 方面的业务扩展而获得 2025 年制药技术卓越奖的 Upperton Pharma Solutions 正在快速扩展其在英国的 GMP 和无菌制造能力。了解 Upperton 的综合 CDMO 模型如何帮助制药公司从早期开发阶段过渡到临床和小众商业供应，减少交接和加快时间表。</p>
<p>发现影响</p>

RPTX

吉利德科学

<p>吉利德科学已同意收购 Repare Therapeutics 的 Polθ ATP 酶抑制剂 RP-3467，交易金额最高可达 3000 万美元。该交易包括 2500 万美元的预付款，以及在技术转让完成后最高可达 500 万美元的付款。这项收购增强了 Repare 的现金储备，影响了股东的分红，预计为每股 2.20 美元。Repare 的首席执行官 Steve Forte 强调此次交易是一个重要的投资组合举措，将吉利德在肿瘤学领域的专业知识与 RP-3467 在靶向 BRCA 突变方面的潜力相结合</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/PT-26-12-2025-shutterstock_2340757177-430x241.jpg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/PT-26-12-2025-shutterstock_2340757177-430x241.jpg"/></p>
<p>RP-3467 is a potent small molecule inhibitor of Polθ, a synthetic lethality target linked to BRCA mutations and other genomic alterations. Credit: PeopleImages/Shutterstock.com.</p>
<div class="lb-trans"><p>RP-3467 是一种强效的小分子 Polθ 抑制剂，属于与 BRCA 突变和其他基因组改变相关的合成致死靶点。来源：PeopleImages/Shutterstock.com。</p>
</div><p>Gilead Sciences has signed an agreement to acquire Repare Therapeutics’ polymerase theta (Polθ) ATPase inhibitor, RP-3467.</p>
<div class="lb-trans"><p>吉利德科学已签署协议收购 Repare Therapeutics 的聚合酶 theta (Polθ) ATP 酶抑制剂 RP-3467。</p>
</div><p>The transaction involves a total consideration of up to $30m to Repare and directly influences the company’s cash status and upcoming shareholder arrangements.</p>
<div class="lb-trans"><p>该交易涉及对 Repare 的总对价高达 3000 万美元，并直接影响公司的现金状况和即将进行的股东安排。</p>
</div><h3>Go deeper with GlobalData</h3>
<div class="lb-trans"><h3>深入了解 GlobalData</h3>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>报告</p>
</div><h4>NPVM: Repare Therapeutics Inc's RP-6306</h4>
<div class="lb-trans"><h4>NPVM: Repare Therapeutics Inc 的 RP-6306</h4>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>报告</p>
</div><h4>NPVM: Replimune Ltd's Vusolimogene Oderparepvec</h4>
<div class="lb-trans"><h4>NPVM: Replimune Ltd 的 Vusolimogene Oderparepvec</h4>
</div><h5>Go deeper with GlobalData</h5>
<div class="lb-trans"><h5>深入了解 GlobalData</h5>
</div><p>The gold standard of business intelligence.</p>
<div class="lb-trans"><p>商业智能的黄金标准。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>了解更多</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>Discover B2B Marketing That Performs</h4>
<div class="lb-trans"><h4>发现有效的 B2B 营销</h4>
</div><p>Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.</p>
<div class="lb-trans"><p>结合商业智能和编辑卓越，覆盖 36 个领先媒体平台的专业人士。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>了解更多</p>
</div><p>According to the terms, Gilead will pay Repare $25m upfront, subject to customary holdbacks and adjustments, and up to an additional $5m upon completion of certain technology transfer activities.</p>
<div class="lb-trans"><p>根据条款，吉利德将向 Repare 支付 2500 万美元的预付款，受制于常规的扣留和调整，并在完成某些技术转让活动后再支付最多 500 万美元。</p>
</div><p>On 14 November 2025, Repare announced a definitive arrangement agreement with XenoTherapeutics and Xeno Acquisition. Under this agreement, Xeno agreed to purchase all of Repare’s issued and outstanding common shares.</p>
<div class="lb-trans"><p>在 2025 年 11 月 14 日，Repare 宣布与 XenoTherapeutics 和 Xeno Acquisition 签署了最终安排协议。根据该协议，Xeno 同意购买 Repare 所有已发行和流通的普通股。</p>
</div><p>The amount of cash each shareholder will receive per share will be based on Repare’s closing cash balance, after subtracting transaction-related expenses and outstanding liabilities.</p>
<div class="lb-trans"><p>每位股东每股将收到的现金金额将基于 Repare 的结算现金余额，扣除与交易相关的费用和未偿债务后计算。</p>
</div><p>The upfront payment from the Polθ ATPase inhibitor acquisition has increased Repare’s cash reserves, thereby raising the estimate for shareholder payments.</p>
<div class="lb-trans"><p>Polθ ATP 酶抑制剂收购的预付款增加了 Repare 的现金储备，从而提高了对股东支付的估计。</p>
</div><p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData Strategic Intelligence</p>
<div class="lb-trans"><p>GlobalData 战略情报</p>
</div><h1>US Tariffs are shifting - will you react or anticipate?</h1>
<div class="lb-trans"><h1>美国关税正在变化 - 你会反应还是预见？</h1>
</div><p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
<div class="lb-trans"><p>不要让政策变化让你措手不及。通过实时数据和专家分析保持主动。</p>
</div><p>By GlobalData</p>
<div class="lb-trans"><p>来自 GlobalData</p>
</div><p>Learn more about Strategic Intelligence</p>
<div class="lb-trans"><p>了解更多关于战略情报</p>
</div><p>Based on the revised cash balance, Repare estimates shareholders will receive about $2.20 per common share upon closing the arrangement transaction.</p>
<div class="lb-trans"><p>根据修订后的现金余额，Repare 估计股东在交易完成时将获得约 2.20 美元的普通股每股收益。</p>
</div><p>Repare Therapeutics president, CEO and chief financial officer Steve Forte said: “We are pleased to announce this transaction which combines Gilead’s leading expertise in oncology research and development with RP-3467, a potential best-in-class Polθ ATPase inhibitor. This marks the third and most significant portfolio transaction for Repare this year.”</p>
<div class="lb-trans"><p>Repare Therapeutics 总裁、首席执行官兼首席财务官 Steve Forte 表示：“我们很高兴宣布这一交易，它将吉利德在肿瘤研究和开发方面的领先专业知识与 RP-3467 这一潜在的最佳 Polθ ATP 酶抑制剂结合在一起。这是 Repare 今年第三笔也是最重要的投资组合交易。”</p>
</div><p>RP-3467 is a potent small molecule inhibitor of Polθ, a synthetic lethality target linked to breast cancer gene (BRCA) mutations and other genomic alterations.</p>
<div class="lb-trans"><p>RP-3467 是一种强效的小分子 Polθ 抑制剂，属于与乳腺癌基因 (BRCA) 突变和其他基因组改变相关的合成致死靶点。</p>
</div><p>In May 2025, Repare entered an out-licensing agreement with Canadian biotechnology firm DCx Biotherapeutics for discovery platforms and intellectual property (IP).</p>
<div class="lb-trans"><p>在 2025 年 5 月，Repare 与加拿大生物技术公司 DCx Biotherapeutics 签署了发现平台和知识产权 (IP) 的外部许可协议。</p>
</div><h2>Pharmaceutical Technology Excellence Awards - Nominations Closed</h2>
<div class="lb-trans"><h2>制药技术卓越奖 - 提名已关闭</h2>
</div><p>Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.</p>
<div class="lb-trans"><p>制药技术卓越奖 的提名现已关闭。感谢所有参与的组织 - 你们的响应非常出色，展示了卓越的创新、领导力和影响力。</p>
</div><p><strong>Excellence in Action</strong></p>
<div class="lb-trans"><p><strong>行动中的卓越</strong></p>
</div><p>Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.</p>
<div class="lb-trans"><p>因在 综合制造 方面的业务扩展而获得 2025 年制药技术卓越奖的 Upperton Pharma Solutions 正在快速扩展其在英国的 GMP 和无菌制造能力。了解 Upperton 的综合 CDMO 模型如何帮助制药公司从早期开发阶段过渡到临床和小众商业供应，减少交接和加快时间表。</p>
</div><p>Discover the Impact</p>
<div class="lb-trans"><p>发现影响</p>
</div>

吉利德科学将收购 Repare Therapeutics 的 RP-3467